Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $150.1 million.

  • Collegium Pharmaceutical's Cash & Equivalents rose 28525.67% to $150.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.1 million, marking a year-over-year increase of 28525.67%. This contributed to the annual value of $70.6 million for FY2024, which is 7046.83% down from last year.
  • Collegium Pharmaceutical's Cash & Equivalents amounted to $150.1 million in Q3 2025, which was up 28525.67% from $117.3 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Cash & Equivalents registered a high of $283.7 million during Q2 2023, and its lowest value of $39.0 million during Q3 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $173.7 million (2022), whereas its average is $169.9 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Cash & Equivalents plummeted by 8493.03% in 2024 and then surged by 28525.67% in 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Cash & Equivalents (Quarter) stood at $186.4 million in 2021, then decreased by 6.83% to $173.7 million in 2022, then surged by 37.57% to $238.9 million in 2023, then tumbled by 70.47% to $70.6 million in 2024, then skyrocketed by 112.71% to $150.1 million in 2025.
  • Its Cash & Equivalents stands at $150.1 million for Q3 2025, versus $117.3 million for Q2 2025 and $96.2 million for Q1 2025.